You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

Drug Price Trends for GNP URINARY PAIN RLF


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for GNP URINARY PAIN RLF

Average Pharmacy Cost for GNP URINARY PAIN RLF

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
GNP URINARY PAIN RLF 99.5 MG 46122-0628-53 0.17952 EACH 2025-01-22
GNP URINARY PAIN RLF 99.5 MG 46122-0628-53 0.18210 EACH 2024-12-18
GNP URINARY PAIN RLF 99.5 MG 46122-0628-53 0.17659 EACH 2024-11-20
GNP URINARY PAIN RLF 99.5 MG 46122-0628-53 0.19561 EACH 2024-10-23
GNP URINARY PAIN RLF 99.5 MG 46122-0628-53 0.18848 EACH 2024-09-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for GNP Urinary Pain Relief

Introduction to GNP Urinary Pain Relief

GNP Urinary Pain Relief is a medication designed to provide temporary relief from the pain and discomfort associated with urinary tract infections (UTIs). The product contains methenamine, an antibacterial agent, and sodium salicylate, a nonsteroidal anti-inflammatory drug (NSAID), which work together to alleviate symptoms such as pain, burning, and the frequency and urgency of urination[2].

Market Context: Urinary Tract Infection Therapeutics

The global urinary tract infection therapeutics market is experiencing significant growth, driven by several key factors. As of 2022, the market was valued at USD 8.92 billion and is projected to reach USD 11.85 billion by 2031, growing at a CAGR of 3.2% during the forecast period (2023-2031)[3].

Key Drivers of the Market

Increasing Prevalence of UTIs

The rising prevalence of urinary tract infections, particularly among the geriatric population and those with conditions like diabetes and kidney stones, is a major driver of the market. In Germany, for example, UTIs are a frequent cause for visits to family medicine, with a prevalence ranging between 1.7 and 3.1%[3].

Launch of Combination Drugs

The introduction of combination drugs that offer both antibacterial and analgesic properties, such as GNP Urinary Pain Relief, is also driving market growth. These combination drugs provide comprehensive relief from UTI symptoms, enhancing patient compliance and outcomes.

Government Initiatives

Government guidelines aimed at preventing drug resistance and promoting the use of effective therapeutics also contribute to the market's expansion. In Europe, specific guidelines are in place to ensure the responsible use of antibiotics and other UTI treatments[3].

Market Segmentation

By Drug Type

The market for urinary tract infection therapeutics is segmented by drug type, with combination drugs like GNP Urinary Pain Relief gaining traction. These drugs combine antibacterial agents with analgesics, providing a dual-action approach to treating UTIs[2].

By Distribution Channel

Hospital pharmacies currently hold the largest share of the market, and this trend is expected to continue. However, retail pharmacies and online channels are also becoming increasingly important distribution channels, especially for over-the-counter (OTC) medications like GNP Urinary Pain Relief[1].

Price Projections and Market Size

Global Urological Disorders Drugs Market

While GNP Urinary Pain Relief is part of the broader urological disorders drugs market, it is essential to consider the overall market size and growth projections. The global urological disorders drugs market was valued at USD 8.94 billion in 2023 and is expected to reach USD 11.93 billion by 2028, growing at a CAGR of 5.94% during the forecast period[4].

Urinary Tract Infection Therapeutics Market

Specific to UTI therapeutics, the market is projected to grow from USD 8.92 billion in 2022 to USD 11.85 billion by 2031. This growth indicates a stable and increasing demand for effective UTI treatments, including combination drugs like GNP Urinary Pain Relief[3].

Pricing Factors

Raw Material Costs

The cost of raw materials, such as methenamine and sodium salicylate, can influence the pricing of GNP Urinary Pain Relief. Fluctuations in these costs can impact the final product price.

Regulatory Environment

Strict regulatory frameworks can affect the pricing strategy of pharmaceutical companies. Compliance with regulatory requirements can add to the production costs, which may be reflected in the final product price[4].

Market Competition

The level of competition in the UTI therapeutics market also plays a crucial role in pricing. With multiple products available, companies may adjust their prices to remain competitive while ensuring profitability.

Price Projections

Given the growth projections of the UTI therapeutics market and the broader urological disorders market, it is likely that the price of GNP Urinary Pain Relief will remain competitive. Here are some potential price projection scenarios:

  • Base Scenario: The price of GNP Urinary Pain Relief is expected to remain stable or see a slight increase, aligning with the overall market growth. This could mean a price range of $10 to $15 per pack, depending on the region and distribution channel.

  • Growth Scenario: If the market experiences higher-than-expected growth due to increased demand or new regulatory approvals, the price could see a moderate increase, potentially reaching $15 to $20 per pack.

  • Competition Scenario: In a highly competitive market, prices might be pressured downward to maintain market share. This could result in a price range of $8 to $12 per pack.

Key Takeaways

  • The global urinary tract infection therapeutics market is growing, driven by increasing prevalence, new drug launches, and government initiatives.
  • GNP Urinary Pain Relief benefits from being a combination drug that addresses multiple symptoms of UTIs.
  • The pricing of GNP Urinary Pain Relief will be influenced by raw material costs, regulatory compliance, and market competition.
  • Price projections suggest stability or a slight increase, with potential ranges from $10 to $20 per pack depending on market conditions.

FAQs

1. What are the key ingredients in GNP Urinary Pain Relief? GNP Urinary Pain Relief contains methenamine as an antibacterial agent and sodium salicylate as an NSAID for pain relief[2].

2. What is the projected growth rate of the urinary tract infection therapeutics market? The urinary tract infection therapeutics market is expected to grow at a CAGR of 3.2% from 2023 to 2031[3].

3. Which segment holds the largest share in the urological disorders drugs market? The hospital pharmacy segment currently holds the largest share in the urological disorders drugs market[1].

4. What are the main drivers of the urological disorders drugs market? The main drivers include the increasing geriatric population, changing lifestyles, and advancements in drug delivery systems[4].

5. How does the regulatory environment impact the pricing of GNP Urinary Pain Relief? The regulatory environment can add to production costs due to compliance requirements, which may be reflected in the final product price[4].

Sources

  1. Nova One Advisor: U.S. Pain Management Drugs Market Size and Growth, Statistics 2024 to 2033.
  2. Drug-OTC: GNP Antibacterial Plus Urinary Pain Relief Tablets.
  3. StraitsResearch: Urinary Tract Infection Therapeutics Market Size, Trends & Growth.
  4. BusinessWire: $11.93 Billion Urological Disorders Drugs Market Analysis, 2023-2028.
  5. Allied Market Research: Pain Management Drugs Market Size, Share | Forecast - 2033.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.